ProShare Advisors’s Unity Biotechnology UBX Stock Holding History

ProShare Advisors’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,177	Closed	-$35K	–	2350
2021 Q3	$35K	Buy	+1,177	New	+$41.5K	﹤0.01%	1985
2021 Q2	–	Sell	-1,678	Closed	-$101K	–	2404
2021 Q1	$101K	Buy	1,678 +76	+5%	+$5.18K	﹤0.01%	2164
2020 Q4	$84K	Buy	1,602 +336	+27%	+$16.2K	﹤0.01%	2009
2020 Q3	$44K	Buy	1,266 +34	+3%	+$2.15K	﹤0.01%	1601
2020 Q2	$107K	Buy	+1,232	New	+$91.4K	﹤0.01%	1564
2020 Q1	–	Sell	-1,382	Closed	-$100K	–	1568
2019 Q4	$100K	Sell	1,382 -92	-6%	-$6.49K	﹤0.01%	1693
2019 Q3	$90K	Sell	1,474 -42	-3%	-$2.97K	﹤0.01%	1563
2019 Q2	$144K	Sell	1,516 -192	-11%	-$16.3K	﹤0.01%	1495
2019 Q1	$139K	Buy	1,708 +11	+0.6%	+$1.25K	﹤0.01%	1533
2018 Q4	$276K	Buy	+1,697	New	+$225K	﹤0.01%	1198

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ProShare Advisors's UBX Position: Q4 2021 in Review

ProShare Advisors sold out of Unity Biotechnology (UBX) in Q4 2021, closing a stake of 1,177 shares — an estimated $35K sold.

ProShare Advisors first reported a position in UBX in Q4 2018 and held it in 10 quarters. The position peaked at $276K in Q4 2018. 71 funds tracked by Wall St. Rank hold UBX as of Q4 2021.

ProShare Advisors reported no remaining Unity Biotechnology position as of Q4 2021 after selling out during the quarter.
ProShare Advisors sold 1,177 Unity Biotechnology shares in Q4 2021, an estimated $35K.
ProShare Advisors first reported a position in Unity Biotechnology in Q4 2018 and held it in 10 quarters.
ProShare Advisors's Unity Biotechnology position peaked at $276K in Q4 2018.
71 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2021.

Based on ProShare Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.